Showing results (131-140 of 366) with videos related to

Sort By:
Pageof 37
British Journal of Cancer|October 2, 2021
Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancerAlex Martinez-Marti, Enriqueta Felip, Francesco Mattia Mancuso, et al.
Clinical Lung Cancer|July 22, 2017
Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based ChemotherapyEnriqueta Felip, Vera Hirsh, Sanjay Popat, et al.
Cancer Discovery|August 17, 2013
Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutationVioleta Serra, Ana Vivancos, Xose S Puente, et al.
Cancers|August 14, 2025
Insights on Oligometastatic Non-Small-Cell Lung CancerAugusto Valdivia, Pau Mascaro-Baselga, Clara Salva-de Torres, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 23, 2022
Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR sectionDomingo Antonio Sanchez Martinez, Aliica Quilez-Cutillas, Pablo Jimenez-Labaig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2016
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2Lucio Crinò, Myung-Ju Ahn, Filippo De Marinis, et al.
Cancer Medicine|April 13, 2026
Second Line Treatment Decision as Per Standard of Care or Foundation Medicine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerFederico Rojo, Enriqueta Felip, Oscar Juan Vidal, et al.
JCO Precision Oncology|January 7, 2022
Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung CancerRamon Palmero, Alvaro Taus, Santiago Viteri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014Benjamin J Solomon, Federico Cappuzzo, Enriqueta Felip, et al.
Computational and Structural Biotechnology Journal|July 15, 2026
MiracleNet: A Biologically Interpretable Machine Learning Model for Resected Non-small-cell Lung CancerRashika Jakhmola, David A Selby, Mert Cihan, et al.
Pageof 37